Junior Chair: Exosomes in valvular calcification
Matthieu Lecuyer recently joined our laboratory on a Junior Professor Chair position at Rouen Normandy University to support research and formation within the Cribier Valve Institute. He will work at EnVI laboratory to investigate the roles of Extra-Cellular Vesicles/Exosomes in valvular calcification, in a project entitled: "Development of innovative treatments for the management of cardiac valvular diseases".
- Valvular heart diseases are common and increasing in prevalence due to population aging, with an incidence comparable to that of Alzheimer’s disease. Their pathophysiology remains poorly understood, and no treatment currently exists to halt or slow their progression. Building on ten years of collaborative experience (FHU/RHU), the Alain Cribier Institute aims to bring together all the key players in the field of cardiac valves on a single site. Matthieu will be responsible for coordinating preclinical and translational research in the field of therapeutic innovation for the management of valvular heart diseases—particularly calcified aortic stenosis—aligned with Axis 2 of INSERM Unit 1096, in collaboration with the Cardiology and Cardiothoracic Surgery Departments of the Rouen University Hospital. His responsibilities include:
- Managing the isolation and study of valvular cells
- Organotypic culture of murine, porcine, or human explanted valves
- In vivo studies in murine models of aortic stenosis, particularly in contexts of kidney failure induced by nephrectomy or metabolic disorders
- Establishing methodologies for studying bioprosthetic valve degeneration in rodents (subcutaneous implantation)
- Setting up a large animal model (sheep or pig) for in vivo investigation of the mechanisms and surgical or pharmacological treatments of aortic stenosis
- Leading and conducting biological studies in support of clinical trials and cohort studies carried out within the Institute.
- Research Background and Expertise

- Matthieu has a background as a polyvalent researcher with extensive experience in Neurosciences field, gained in France, USA and Switzerland in various sectors, including academia and the private sector (biotech startup).
- In 2017, he obtained his PhD in molecular biology /neurosciences at Inserm UMR1245 Rouen University Normandy, studying the 'Impact of magnesium sulfate and fetal alcohol exposure on neurovascular interactions during development', under guidance by Dr. Bruno Gonzalez. During his thesis, Matthieu contributed to several articles (e.g. PMID: 38269113, 30340542, 28805973,
- 28587682, 30671527, 28922852) as well as 2 patents: i) The first biomarker of ‘brain alcohol effect’, which may help in early diagnosis, and ii) Validation of a Therapeutic Target for fetal alcohol exposure.
- Then, he moved to the US in 2018 for a postdoc at UCSF (University of California San Francisco), where he participated in two major projects: i) Neonatal stroke and Extra-Cellular Vesicles/Exosome modulation, and 2) Effects of Omega-3 on neonatal stroke. This experience led to several publications (e.g. PMID: 34153465, 34235636, 34674145, 32269105 ), and establishment of Matthieu as an expert on extra-cellular vesicles.
- Subsequently, Matthieu moved to Switzerland to join a start-up company (Mosaic NeuroSciences). Here, Matthieu spearheaded the establishment and management of a new research laboratory, and he established a new research direction by investigating the potential of genetic decoration of neural exosomes with proprietary biopolymer to extend the exosome's half-life in plasma.
